IN8bio Inc Aktie News

Renommierte Expertin für γδ-T-Zellen und T-Zell-Engager (TCE) bringt zwei Jahrzehnte Erfahrung in Wirkstoffforschung und -entwicklung zu IN8bio; die Ernennung stärkt die Führungs- und Fachkompetenz von IN8bio, während das Unternehmen seine neuartige γδ-T-Zell-Engager-Plattform vorantreibt NEW YORK, 9. Sept. 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), ein biopharmazeutisches Unternehme...

Erste peer‑reviewte Veröffentlichung klinischer Ergebnisse zu chemotherapie‑resistenten Gamma‑Delta‑T‑Zellen (DeltEx Drug Resistant Immunotherapy bzw. DRI) bei neu diagnostiziertem Glioblastom Wiederholte Dosenpatienten erreichten ein medianes progressionsfreies Überleben (mPFS) von 16,1 Monaten, damit mehr als das Doppelte des etwa 6,9‑monatigen Standard‑of‑Care‑Benchmarks, ohne dosislimitiere...

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “Harnessing γδ T cells through engineering and combination therapies” in the journal Nature Communicat...

Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.

Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026 Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026 Hosting R&D Day on May 21, 2026 in New York City NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc.  (Nasdaq: INAB),...

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) (“IN8bio” or the “Company”), a clinical-stage biopharmaceutical company developing innovative gamma-delta (“γδ”) T cell therapies for cancer and autoimmune diseases, today announced a series of presentations at leading medical and scientific conferences in May and June 2026, including new clinical data at the American Societ...

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 11,800 shares of its comm...